| 1 |
33405090 | Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma. | 2021 Jun |
1 |
| 2 |
33683166 | Selumetinib: the first ever approved drug for neurofibromatosis-1 related inoperable plexiform neurofibroma. | 2021 May |
1 |
| 3 |
32880495 | Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation. | 2020 Nov |
1 |
| 4 |
27100819 | Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. | 2016 Jun 1 |
1 |
| 5 |
24938562 | Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial. | 2014 Jun 18 |
1 |
| 6 |
25278770 | Profile of selumetinib and its potential in the treatment of melanoma. | 2014 |
1 |
| 7 |
23200175 | Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. | 2013 Jan |
1 |
| 8 |
23406027 | Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. | 2013 Feb 14 |
3 |
| 9 |
22394161 | Selumetinib (AZD6244; ARRY-142886) in the treatment of metastatic melanoma. | 2012 Apr |
1 |